Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

CEREVEL THERAPEUTICS HOLDINGS, INC.

(CERE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Cerevel Therapeutics Hosts Virtual R&D Event to Review CVL-871 in Dementia-Related Apathy and Provide Update on CVL-231 for the Treatment of Schizophrenia

10/07/2021 | 07:00am EST

Cerevel Therapeutics will host a virtual R&D event from 10:00 to 11:30 a.m. ET. Presented in a live webcast format, Cerevel will discuss CVL-871, a dopamine D1/D5 receptor partial agonist in development for the treatment of dementia-related apathy, and provide an update on CVL-231, a muscarinic M4 positive allosteric modulator in development for the treatment of schizophrenia. This R&D event is one of a series of virtual webcasts dedicated to providing in-depth discussions on key portfolio programs. CVL-871 is currently being studied in a Phase 2a exploratory trial to evaluate the compound as a potential treatment for dementia-related apathy. Apathy is among the most common neuropsychiatric co-morbidities associated with dementia, is one of the strongest predictors of disease progression, and is associated with higher mortality risk and early institutionalization. During today’s discussion, key members of Cerevel’s scientific and clinical teams will be joined by Dr. Krista Lanctot, Professor of Psychiatry and Pharmacology/Toxicology at the University of Toronto, a leading expert in the neuropsychiatric manifestations of dementia, including apathy. Cerevel received Fast Track designation for the development of CVL-871 in this indication from the U.S. Food and Drug Administration earlier this year. Data from the ongoing Phase 2a trial are expected in the second half of 2022. CVL-231 is in development as a potential treatment for schizophrenia. In June, Cerevel announced positive topline results from its Phase 1b trial of CVL-231 and plans to initiate a comprehensive Phase 2 development program. Cerevel also intends to explore CVL-231 for other populations, including dementia-related psychosis. CVL-871 is a selective dopamine D1/D5 partial agonist specifically designed to achieve a level of partial agonism that is anticipated to modulate the complex neural networks that govern apathy-related behaviors in neurodegenerative diseases. In June 2021, Cerevel received Fast Track Designation from the U.S. Food and Drug Administration for CVL-871 for the treatment of dementia-related apathy. Cerevel began screening patients in an exploratory Phase 2a trial of CVL-871 for dementia-related apathy in the second quarter of 2021, with data expected in the second half of 2022. CVL-231 is a positive allosteric modulator designed to selectively target the M4 muscarinic receptor. M4 muscarinic receptors have been shown to influence the activation levels of acetylcholine, and subsequently, dopamine receptors, key neurotransmitter pathways in the brain that are known to be dysregulated in patients with schizophrenia. Topline results from a Phase 1b trial of CVL-231 in schizophrenia found both doses of the therapy demonstrated a clinically meaningful and statistically significant improvement in the Positive and Negative Syndrome Scale (PANSS) total score at six weeks and were overall well-tolerated compared with placebo. Cerevel plans to advance CVL-231 to a comprehensive Phase 2 development program in schizophrenia and to evaluate the potential for this mechanism in other populations, including dementia-related psychosis.


© S&P Capital IQ 2021
All news about CEREVEL THERAPEUTICS HOLDINGS, INC.
11/10Cerevel Therapeutics Corporate Presentation
PU
11/10Cerevel Therapeutics Reports Third Quarter 2021 Financial Results and Pipeline Updates ..
PU
11/10CEREVEL THERAPEUTICS HOLDINGS, INC. Management's Discussion and Analysis of Financial ..
AQ
11/01Cerevel Therapeutics to Participate at Upcoming Virtual Investor Conferences
AQ
10/20CEREVEL THERAPEUTICS : to Report Third Quarter 2021 Financial Results on Wednesday, Novemb..
AQ
10/08CEREVEL THERAPEUTICS : Jefferies & Co Adjusts Cerevel Therapeutics Holdings PT to $37 From..
MT
10/07CEREVEL THERAPEUTICS : R&D Day Presentation
PU
10/07CEREVEL THERAPEUTICS : Hosts Virtual R&D Event to Review CVL-871 in Dementia-Related Apath..
GL
10/07Cerevel Therapeutics Hosts Virtual R&D Event to Review CVL-871 in Dementia-Related Apat..
CI
09/21CEREVEL THERAPEUTICS : Announces Departure of CFO Kathy Yi (Form 8-K)
PU
More news
Analyst Recommendations on CEREVEL THERAPEUTICS HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2021 - - -
Net income 2021 -226 M - -
Net cash 2021 609 M - -
P/E ratio 2021 -18,8x
Yield 2021 -
Capitalization 4 607 M 4 607 M -
EV / Sales 2021 -
EV / Sales 2022 -
Nbr of Employees 168
Free-Float 81,3%
Chart CEREVEL THERAPEUTICS HOLDINGS, INC.
Duration : Period :
Cerevel Therapeutics Holdings, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CEREVEL THERAPEUTICS HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 31,29 $
Average target price 46,33 $
Spread / Average Target 48,1%
EPS Revisions
Managers and Directors
N. Anthony Coles Executive Chairman & Chief Executive Officer
Abraham N. Ceesay President
Mark Bodenrader VP-Finance, Chief Financial & Accounting Officer
John Renger Chief Scientific Officer
Raymond Sanchez Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
CEREVEL THERAPEUTICS HOLDINGS, INC.88.72%4 607
GILEAD SCIENCES, INC.21.27%88 622
BIONTECH SE344.70%87 556
REGENERON PHARMACEUTICALS35.46%68 421
WUXI APPTEC CO., LTD.27.38%66 062
VERTEX PHARMACEUTICALS-19.56%48 336